A growing body of research points to the role of the gut-brain axis in the development of Parkinson disease, with inflammatory bowel disease, leaky gut, and altered gut microbiota observed in the gut, often years before the onset of symptoms of Parkinson disease.
Patients with Parkinson disease (PD) who use inappropriate antipsychotics may be at an increased risk for pneumonia compared with patients with PD who use more appropriate atypical antipsychotics.
Published studies that included data on the risk for PD in patients with BD vs the general population without BD were included in a systematic review.
Nourianz is now available as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.
The risk factors for tardive dyskinesia in patients taking antipsychotics include age, comorbid diagnoses, and high medication dosages.
An expert subcommittee of the AAN has released an updated evidence-based clinical practice guideline on treating Tourette syndrome and other chronic tic disorders.
Consistent with primary KINECT 3 study results, supplemental analyses indicate that participants treated with valbenazine had statistically significant improvements in tardive dyskinesia severity.
The integration of technology into medicine has expanded into various uses in patients with Parkinson disease.
Levodopa pill can wear off, but a powdered version can help patients during off periods.
Progression of infant motor development is associated with cognitive ability in later childhood.
